Publication of and access to clinical-trial data
By Dr Wolfgang A Rehmann and Diana Heimhalt
The European Medicines Agency (EMA) is currently developing a policy on the proactive publication of clinical-trial data. Formerly, the EMA had adopted a policy on access to its documents, which the EMA stated would allow documents submitted to it as part of a marketing authorisation application, such as clinical-trial reports, to be disclosed, provided that the decision-making process for the application in question was finalised. However, in interim proceedings, the European Union General Court (EGC) suspended the operation of such EMA decisions concerning the granting of third-party access to documents held by the EMA, which contain information submitted by an undertaking as part of its application for authorisation to place a medicinal product on the market
On 24 June 2013, the EMA released a new draft policy on publication and access to clinical-trial data for a three-month public consultation. The draft follows a process that the EMA started in 2010. Before 2010, the EMA refused access to clinical study reports because it would undermine the commercial interests of the manufacturers of those medicinal products. However, after a complaint filed by a research and information centre to the European Ombudsman and his conclusion that the relevant reports did not contain commercially confidential information, the EMA decided to grant access to those reports and committed itself to taking appropriate measures in order to implement the Ombudsman’s recommendations…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
For the tax year from 6 April 2014, the standard lifetime allowance has reduced from £1.5m to £1.25m.
One of the areas highlighted last year by the Regulator was the regulation of workplace DC pension schemes.
Analysis from The Lawyer
As the equity capital markets rocketed back into favour and global M&A saw at least a partial return to form, there have been some rich pickings for The Lawyer’s Corporate Team of the Year award shortlisted firms in 2014.
The city-state is working hard to become a global wealth management hub, and law firms are gearing up for a prosperous new world